1.1.1 - US Pharmaceutical Stakeholder Map
US pharmaceutical stakeholder map
A medicine reaches a patient through overlapping product, benefit, clinical, and financial relationships. A useful stakeholder map identifies who performs each function, who has decision authority, and which transactions connect them.
Why it matters
- Product availability does not establish coverage, a payable claim, an authorized dispensing location, or an affordable patient payment.
- Access work stalls when a manufacturer account team approaches a supplier about a benefit decision or treats an administrator as the party financing claims.
- The supplied course blueprint places IRA negotiation and government pricing within launch strategy. Before analyzing those policies, identify which program and transaction are involved.
- A stakeholder map connects an observed barrier to a decision owner, a document to inspect, and an actionable next step.
Key Terms & Must-Know Facts
- Manufacturer
- Organization responsible for supplying its medicine and managing relevant pricing, contracting, and program responsibilities.
- Wholesaler or distributor
- Intermediary that supports product distribution and associated commercial transactions; the precise functions depend on the arrangement.
- Retail or specialty pharmacy
- Dispensing organization. Specialty pharmacies may also coordinate access and product-specific services under applicable arrangements.
- Health plan
- Organization administering or offering health coverage; its financing and delegated functions must be identified separately.
- Pharmacy benefit manager
- A PBM administers contracted pharmacy-benefit functions. Authority over claims, networks, formularies, and contracting depends on delegation.
- Self-funded employer
- Employer that finances covered claims under its benefit arrangement while potentially hiring other organizations to administer them.
- Formulary committee
- Body that evaluates medicines and makes recommendations or decisions within its assigned governance process.
- Integrated delivery network
- An IDN connects care organizations and may coordinate local clinical, purchasing, and operational decisions.
- Group purchasing organization
- A GPO supports purchasing arrangements for participating organizations; purchasing influence does not establish payer coverage authority.
- Claim
- Request for payment or benefit adjudication associated with a service or dispensed product.
- Rebate
- Payment or adjustment determined under a contract or program; the recipient, basis, and timing must be established.
- Chargeback
- In a common wholesaler arrangement, a settlement addressing the difference between a wholesaler's acquisition price and an eligible customer's contract purchase price.
- Patient payment
- The amount the patient pays under the applicable transaction and benefit rules; it is not automatically the product's list price.
- Specialty network
- Set of designated providers or pharmacies within an arrangement; participation must be checked for the specific benefit and product.
Must-know facts
- Separate physical custody, decision authority, and financial responsibility before drawing arrows.
- One organization can perform several roles, but those roles should remain distinct on the map.
- Employer-sponsored coverage may be insured or self-funded; the employer's name alone does not identify the funding model.
- Medicare, Medicaid, and federal purchasing channels require different program labels.
- Clinical recommendations, coverage criteria, purchasing contracts, and network requirements answer different questions.
- Each financial arrow needs a sender, recipient, transaction type, and supporting record.
| Stakeholder | Primary mapping question | Useful evidence |
|---|---|---|
| Manufacturer | Who supplies the medicine and owns the relevant agreement? | Distribution and pricing agreements |
| Wholesaler or distributor | Who moves product or settles eligible customer pricing? | Invoices, shipment records, chargeback records |
| Retail or specialty pharmacy | Who dispenses, submits the pharmacy claim, and collects patient payment? | Dispensing records, adjudication response, network terms |
| Health plan or delegated PBM | Who applies the relevant coverage or benefit rule? | Benefit documents, delegation agreement, coverage criteria |
| Hospital, health system, or IDN | Who controls local care delivery and operational adoption? | Local governance, purchasing, and implementation records |
| GPO | Which purchasing agreement applies? | Contract eligibility and purchasing terms |
| Employer | Who sponsors and finances the benefit? | Funding arrangement and administrative agreement |
| Patient | What remains unresolved between coverage and receiving treatment? | Benefit information, claim outcome, dispensing status |
Core content
1.1.1.1 1. Separate organizations from functions
A Explanation: supplier versus access decision maker
WHY THIS IS TESTED: An organization name is an unreliable substitute for a defined function. The practical conflict is whether to contact the party moving the medicine or the party controlling the barrier.
Start with the patient-facing event: a medicine cannot be obtained, a claim is rejected, a clinic has not adopted the product, or an invoice price is disputed. Assign that event to a function before assigning it to an organization. A distributor can confirm supply without determining benefit coverage. A pharmacy can identify an adjudication problem without owning the policy that caused it.
Use separate role labels even when entities share ownership. An integrated organization may include a health plan, PBM, specialty pharmacy, and care delivery network. Corporate affiliation does not tell you which team can change a specific decision. See Fig 1.
Exam takeaway: Identify the function controlling the barrier before selecting an organization to contact.
graph TD; A[Manufacturer] -->|Product| B[Wholesaler or distributor]; B -->|Product| C[Pharmacy or care site]; C -->|Dispensing or administration| D[Patient]; E[Plan or delegated administrator] -->|Benefit rules| C; F[Employer or program] -->|Benefit framework| E;
Exam takeaway: Shared ownership does not collapse coverage, dispensing, and purchasing responsibilities into one decision.
{"prompt":"Square educational vector illustration on white background showing one parent organization above three separate labeled desks: Health plan coverage, PBM administration, Specialty pharmacy dispensing. Thin blue and gray outlines with teal accent; distinct staff and documents at each desk; no ownership implications beyond the hypothetical parent; no logos, numbers, or policy claims.","caption":"Separate functions within a hypothetical organization","size":"1024x1024"}Exam takeaway: A stocked product can still face a separate benefit or dispensing barrier.
{"prompt":"Professional educational comparison illustration, square white background, two equal panels. Left: medicine cartons at a distributor labeled Product available. Right: pharmacist reviewing a benefit response labeled Coverage unresolved. Adult patient waits calmly between panels. Blue and gray flat vector style with teal accent, generous margins, no drug names, prices, or clinical advice.","caption":"Supply status versus access status","size":"1024x1024"}Exam takeaway: A precise problem statement makes the appropriate stakeholder easier to identify.
B Worked example: supply confirmation does not resolve coverage
A 58-year-old patient with rheumatoid arthritis and hypertension is prescribed a hypothetical specialty medicine. A mildly elevated cholesterol result appears in the referral. The distributor confirms stock, and an account representative concludes that patient access is secured. The pharmacy reports an unresolved benefit authorization requirement.
- Identify the task: Determine the most appropriate next stakeholder for the authorization barrier.
- Extract key facts: Supply is confirmed; benefit authorization is unresolved. The cholesterol result does not identify the decision owner.
- Apply the rule: Locate the plan or delegated administrator responsible for the relevant coverage criteria.
- Eliminate: Another stock inquiry cannot answer whether the authorization requirement is met.
- Verify: Obtain the actual benefit response and route the request through the authorized process.
C Common trap: treating ownership as authority
Wrong answer: Ask the affiliated specialty pharmacy to rewrite the plan's criteria. Why tempting: The pharmacy shares the plan's parent organization and handles the patient referral. Single eliminating clue: The question concerns ownership of coverage criteria, which requires confirmed governance or delegation.
D Checkpoint
A manufacturer needs to understand a rejected benefit authorization. Which initial contact is most appropriate?
- A. The wholesaler's inventory team.
- B. The plan or delegated administrator responsible for the requirement.
- C. The pharmacy's product receiving team.
- D. The health system's purchasing-contract team.
Answer: B. A is tempting because availability affects access, but inventory does not determine this requirement. B is correct because the identified barrier is benefit authorization. C is tempting because the pharmacy holds the referral, but receiving staff address product intake. D is tempting because purchasing affects institutional availability, but no purchasing dispute is described.
1.1.1.2 2. Classify the benefit and funding arrangement
A Explanation: administrator versus financial sponsor
WHY THIS IS TESTED: The organization shown on a benefit card may administer services without financing covered claims. The decision conflict is whether a recognizable administrator also bears the arrangement's claims risk.
For commercial coverage, distinguish an insured arrangement from a self-funded employer arrangement. In a self-funded arrangement, the employer finances covered claims while contracted organizations may administer the benefit. Benefit design, formulary options, networks, and delegated authority must be established from the actual arrangement rather than inferred from branding.
Classify public programs separately. Medicare is not Medicaid. Medicaid requires attention to state program context and fee-for-service versus managed care arrangements. TRICARE should not be treated as interchangeable with VA purchasing or a direct DoD purchase. Likewise, the Public Health Service and other federal purchasers are not simply commercial PBM accounts. See Fig 2.
Exam takeaway: The benefit administrator and the party financing claims can be different organizations.
graph TD; A[Identify benefit arrangement] --> B[Commercial insured]; A --> C[Self funded employer]; A --> D[Public program]; B --> E[Identify insurer and administrator]; C --> F[Identify employer funding and administration]; D --> G[Identify specific program and pathway];
| Arrangement | Initial classification task | Do not assume |
|---|---|---|
| Commercial insured | Identify the insurer and delegated benefit functions. | A familiar administrator uses identical rules across all products. |
| Self-funded employer | Identify the employer funder and contracted administrators. | The card's administrator finances covered claims. |
| Medicare | Identify the applicable coverage and reimbursement pathway. | All Medicare medicines follow one benefit process. |
| Medicaid | Identify state context and fee-for-service or managed care. | Managed care utilization is outside the rebate framework. |
| TRICARE | Identify the specific benefit and delivery arrangement. | Its pathway is identical to a VA procurement arrangement. |
| VA or DoD purchasing | Identify the purchasing agreement and covered purchaser. | A negotiated purchasing price establishes every coverage decision. |
| Public Health Service or other federal channel | Identify the entity, program, and applicable purchasing framework. | Every federal transaction has the same requirements. |
The supplied blueprint identifies manufacturer Medicaid participation, federal purchasing agreements, and Medicare reimbursement as separate obligations. This lesson does not calculate their prices or establish the applicability of a particular statutory discount.
Exam takeaway: Contracted administration does not establish who finances the benefit.
{"prompt":"Square side-by-side professional educational vector illustration on white. Left panel labeled Self-funded employer: employer office connected to a Claims funding document. Right panel labeled Administrator: service team reviewing Benefit operations document. Between them a clearly labeled Administrative agreement. Blue gray palette and teal accent; no dollar figures, logos, or claim that all arrangements are identical.","caption":"Funding and administration are separate roles","size":"1024x1024"}Exam takeaway: Program identification comes before applying a pricing or access rule.
B Worked example: a recognizable card creates a false inference
A 46-year-old employee with psoriasis and type 2 diabetes presents a card bearing a national administrator's logo. A blood pressure of 138/84 is recorded in the referral. The employer's benefits team confirms a self-funded arrangement. An access analyst assigns the administrator as the claims funder because its name appears most prominently.
- Identify the task: Assign funding and administration roles correctly.
- Extract key facts: The employer explicitly confirms self-funding; the logo identifies a visible service relationship.
- Apply the rule: Label the employer as the benefit funder and investigate the administrator's contracted functions.
- Eliminate: Branding is not evidence that the administrator finances covered claims; the blood pressure does not resolve this business question.
- Verify: Check benefit and administrative documents before routing a benefit-design request.
C Common trap: treating public channels as one purchaser
Wrong answer: Use the same account pathway for every federal beneficiary and purchaser. Why tempting: Federal involvement appears to create a single category. Single eliminating clue: The named program or purchaser differs, so its benefit or purchasing framework must be identified separately.
D Checkpoint
A self-funded employer contracts with a health plan and PBM. Which statement best describes the map?
- A. The PBM necessarily finances claims because it adjudicates them.
- B. The health plan necessarily finances claims because it provides the network.
- C. The employer finances covered claims, while contracted organizations may administer functions.
- D. The dispensing pharmacy finances covered claims because it collects patient payment.
Answer: C. A is tempting because adjudication looks like payment ownership, but administration does not establish funding. B is tempting because network access is a visible plan function, but this arrangement is self-funded. C correctly separates funding from administration. D is tempting because the pharmacy participates in settlement, but dispensing and collection do not make it the benefit funder.
- True or false: An administrator's logo proves it finances claims. False.
- Before applying a public-program rule, identify the specific program and pathway.
- One organization performs several functions. Should the map merge those functions? No; preserve their separate responsibilities.
1.1.1.3 3. Assign the access decision to the right owner
A Explanation: clinical evaluation versus coverage versus purchasing
WHY THIS IS TESTED: An access restriction may reflect payer criteria, local adoption, network participation, or product supply. These barriers can look similar to the patient but require different interventions.
Ask what must change. A medical director or pharmacy director may participate in benefit policy, case review, or implementation within assigned responsibilities. A formulary committee may evaluate evidence and make recommendations or decisions under its charter. A GPO purchasing arrangement addresses procurement terms. A health system or IDN may control local operational adoption. A specialty network may determine designated service locations under the applicable arrangement.
Choose the stakeholder whose authority matches the requested change. Reject shortcuts based on job title alone. A favorable formulary discussion does not establish an effective coverage date, a network exception, or local stocking. See Fig 3.
Exam takeaway: Coverage, network, procurement, and local adoption require different evidence and owners.
graph TD; A[Define unresolved barrier] --> B{What must change}; B -->|Benefit criteria| C[Plan or delegated coverage owner]; B -->|Dispensing location| D[Network administrator]; B -->|Purchase terms| E[Purchasing team or GPO arrangement]; B -->|Local implementation| F[Health system or IDN governance];Exam takeaway: A positive coverage status does not establish that a care site is ready to deliver the medicine.
graph TD; A[Patient access assessment] --> B[Coverage workstream]; A --> C[Care site workstream]; B --> D[Criteria and authorization status]; C --> E[Supply and operational readiness]; D --> F[Reconcile remaining barriers]; E --> F;
Exam takeaway: Evidence review, purchasing, and network operations are distinct access functions.
{"prompt":"Square educational illustration with three clearly separated workstations labeled Evidence review, Purchasing, and Network operations. At each station show a different document: clinical evidence summary, purchase agreement, participating pharmacy directory. A market access professional holds a card reading Identify the barrier. Flat blue and gray vector style with teal accent on white; no clinical recommendations or institutional logos.","caption":"Match the access question to its owner","size":"1024x1024"}Exam takeaway: A named owner is useful only when its authority matches the requested action.
B Worked example: purchase eligibility does not establish network eligibility
A 63-year-old patient with inflammatory bowel disease and chronic kidney disease has a referral for a hypothetical specialty medicine. A stable hemoglobin result is included. The health system can purchase the product under its agreement, but the patient's benefit designates a different specialty pharmacy. The account team proposes asking the GPO to reverse the network restriction.
- Identify the task: Resolve the dispensing-location barrier.
- Extract key facts: Purchase access exists; benefit network participation remains unresolved. The stable laboratory result does not identify network authority.
- Apply the rule: Contact the responsible network administrator and establish the applicable options.
- Eliminate: The GPO agreement is relevant to purchasing, not evidence that the GPO can change benefit network rules.
- Verify: Confirm the designated pharmacy, any applicable exception process, and referral handoff before promising a dispensing date.
C Common trap: promoting a recommendation into a completed implementation
Wrong answer: Announce unrestricted access immediately after a committee's favorable recommendation. Why tempting: The evidence review appears to be the decisive milestone. Single eliminating clue: The record documents a recommendation, not implemented benefit and operational requirements.
D Checkpoint
A health system has favorable purchasing terms, but its internal process has not authorized local adoption. Which initial owner best matches the barrier?
- A. The relevant health system or IDN governance team.
- B. The external PBM rebate settlement team.
- C. The wholesaler's chargeback processing team.
- D. The employer's benefit funding team.
Answer: A. A is correct because the unresolved decision is local adoption. B is tempting because PBMs influence access, but no pharmacy-benefit decision is described. C is tempting because purchase terms are favorable, but settlement cannot substitute for local approval. D is tempting because employers fund some benefits, but no employer benefit-design issue is stated.
1.1.1.4 4. Trace product, claims, and financial transactions separately
A Explanation: rebate versus chargeback versus patient payment
WHY THIS IS TESTED: Financial arrows can be mistaken for physical movement or for one another. The practical conflict is whether a settlement relates to an eligible customer's purchase price, a rebate agreement, or the patient's benefit transaction.
Draw a product layer first: manufacturer to wholesaler or distributor, then to a dispensing or care site, then to the patient. Direct and alternative distribution arrangements can differ; do not force every product into this illustrative route. Add a claims layer showing which party submits the claim and which organization adjudicates it. Finally, add financial relationships with explicit labels.
In a common chargeback arrangement, a wholesaler acquires product at one price and sells to an eligible customer at a contract price. The chargeback addresses the relevant difference under that agreement. A rebate instead arises under its own program or contract and may involve different parties and timing. Patient payment is another transaction, established through the applicable benefit and dispensing process. See Fig 4.
Exam takeaway: Classify a payment by its contractual purpose rather than by the fact that money moves after a sale.
graph TD; A[Investigate payment] --> B{What does it settle}; B -->|Eligible purchase price difference| C[Evaluate chargeback agreement]; B -->|Contract or program rebate| D[Evaluate rebate terms]; B -->|Patient benefit responsibility| E[Evaluate adjudicated patient payment];Exam takeaway: A shipment record establishes movement, while a claim response addresses a benefit transaction.
graph TD; A[Manufacturer] -->|Product| B[Wholesaler]; B -->|Product| C[Pharmacy]; C -->|Dispensed product| D[Patient]; C -->|Claim| E[Plan or PBM administrator]; E -->|Adjudication response| C; D -->|Patient payment| C;
| Transaction | Distinguishing purpose | Record to inspect | Misleading resemblance |
|---|---|---|---|
| Chargeback | Reconciles an eligible customer's contract purchase price under the distribution agreement. | Customer eligibility, invoice, contract, settlement request | May occur after sale, as a rebate can. |
| Rebate | Meets an applicable rebate contract or program obligation. | Agreement, eligible utilization, calculation and settlement records | May reduce net economics without changing the visible shipment. |
| Claim payment | Settles a covered service or dispensing transaction under the benefit. | Claim and remittance information | Involves a payer but is not thereby a rebate. |
| Patient payment | Represents the patient's responsibility in the applicable transaction. | Adjudicated response and collection record | May be confused with list price or total reimbursement. |
Exam takeaway: The settlement basis distinguishes a chargeback from a rebate.
{"prompt":"Square two-panel educational vector illustration on white. Left titled Chargeback, showing wholesaler invoice and eligible customer contract price document connected to manufacturer settlement record. Right titled Rebate, showing agreement and eligible utilization report connected to rebate settlement record. Blue gray palette, teal accent, minimal text, no numerical formulas, no universal direction of rebate payment implied.","caption":"Compare settlement purposes","size":"1024x1024"}Exam takeaway: Check the claim outcome and dispensing status rather than inferring access from shipment alone.
{"prompt":"Square clean professional vector illustration on white showing access analyst reviewing three separate cards labeled Shipment record, Claim response, and Dispensing status. Adult patient and pharmacist in a small adjacent vignette with a Patient payment receipt. Blue gray palette and teal accent; no monetary values, no guarantees, no medicine branding, generous white border.","caption":"Use distinct records for distinct access questions","size":"1024x1024"}Exam takeaway: Establish the transaction's basis before assigning its financial meaning.
B Worked example: a chargeback is not a patient rebate
A hospital treats a 70-year-old patient with cancer and hypertension. An unchanged creatinine result accompanies the administrative record. In a hypothetical purchasing arrangement, a wholesaler acquired one package for $100 and sold it to an eligible hospital for a $90 contract price. A colleague labels the resulting $10 settlement a patient rebate because it occurs after the sale.
- Identify the task: Classify the settlement, not determine coverage or clinical suitability.
- Extract key facts: The parties are a wholesaler, manufacturer, and eligible purchasing customer; the settlement concerns contract purchase pricing.
- Apply the rule: Under the stated illustrative agreement, the transaction is a chargeback. Its simplified difference is \(100-90=10\) dollars per package.
- Eliminate: Post-sale timing alone does not make it a rebate, and no patient-benefit transaction is described.
- Verify: Match contract eligibility, package units, invoice, and settlement terms. The arithmetic does not establish any government pricing metric or patient payment.
Integrated mini-scenario: A specialty pharmacy receives product through a wholesaler, submits a claim to a delegated administrator, and collects the adjudicated patient amount. Separately, a manufacturer may owe a rebate under an applicable agreement. Record these as separate arrows. Do not net them together until their units, eligible utilization, recipient, and period have been reconciled.
C Common trap: using one price to describe every transaction
Wrong answer: Report the contract purchase price as the patient's payment. Why tempting: Both values concern the same package of medicine. Single eliminating clue: The identified price belongs to a purchasing agreement, not the patient's adjudicated benefit transaction.
D Checkpoint
A wholesaler requests settlement for the difference between its acquisition price and an eligible customer's contract purchase price. What is the best initial classification?
- A. Patient cost sharing.
- B. Claim reimbursement.
- C. Contractual rebate based on utilization.
- D. Chargeback under the purchasing arrangement.
Answer: D. A is tempting because a lower purchase price may be associated with affordability, but no patient responsibility is described. B is tempting because a transaction is being settled, but this is not benefit claim adjudication. C is tempting because rebates also adjust economics, but the stated basis is the customer's purchase-price difference. D matches the described chargeback mechanism.
- Which record answers whether a pharmacy claim adjudicated? The claim response.
- Which clue identifies the illustrative chargeback? An eligible customer's contract purchase-price difference.
- Does a purchasing agreement establish the patient's payment? No.
Exam Traps & Differentiators
- Use the largest organization on the map as the decision owner. Tempting because size suggests influence; the eliminating clue is a specific delegation or governance boundary.
- Interpret a successful product shipment as completed access. Tempting because the medicine is physically available; the eliminating clue is an unresolved claim or patient handoff.
- Send a price-settlement problem to a clinical committee. Tempting because the committee evaluated the product; the eliminating clue is that the dispute concerns an invoice or agreement.
| If the record says | It supports | It does not establish |
|---|---|---|
| Distributor has inventory | Supply availability at that location | Benefit authorization |
| Committee recommends addition | A governance milestone | Completed implementation across all accounts |
| Customer is contract eligible | Purchasing eligibility under stated terms | Patient network eligibility |
| Employer is self-funded | Employer financing of covered claims | Which operational functions are delegated |
Pattern recognition: If the record says authorization, investigate benefit criteria; if it says designated pharmacy, investigate the network; if it says contract invoice discrepancy, investigate purchasing and settlement; if it says local adoption pending, investigate care-organization governance.
Algorithm / Approach
Use this five-step approach before selecting an account action. See Fig 5.
Exam takeaway: A defensible next step connects the barrier, owner, evidence, and verified outcome.
graph TD; A[Define the access barrier] --> B[Classify benefit and funding]; B --> C[Assign authorized decision owner]; C --> D[Trace product claim and money records]; D --> E[Verify resolution and patient handoff];
Useful work product: A one-page map with role-labeled organizations, distinct transaction arrows, governing documents, unresolved questions, and an owner for each next action.
Self-check quiz
1. Foundational: A pharmacy has product in stock but reports a benefit authorization requirement. Which next step best matches the barrier?
- A. Confirm the distributor's next shipment.
- B. Identify the plan or delegated authorization owner.
- C. Request a revised GPO purchase agreement.
- D. Reconcile the wholesaler's acquisition invoice.
2. Foundational: A benefits document explicitly identifies an employer arrangement as self-funded. Who finances covered claims under that arrangement?
- A. The contracted PBM.
- B. The participating pharmacy.
- C. The employer.
- D. The network administrator.
3. Applied: A health system can purchase a product, but the patient's plan designates a different dispensing pharmacy. Which issue should be investigated first?
- A. The applicable specialty network requirement.
- B. The wholesaler's chargeback settlement timing.
- C. The GPO's customer purchase-price eligibility.
- D. The manufacturer's product shipment allocation.
4. Applied: A payment reconciles a wholesaler's acquisition price with an eligible customer's contract purchase price. What best classifies the transaction?
- A. A pharmacy claim payment.
- B. Patient cost sharing.
- C. A utilization-based rebate.
- D. A chargeback.
5. Integrated: A launch team labels one account simply federal and applies a VA purchasing assumption to a TRICARE access question. What is the most appropriate next step?
- A. Replace the assumption with a commercial PBM benchmark.
- B. Identify the specific program, delivery arrangement, and governing documents.
- C. Retain the assumption because both involve federal institutions.
- D. Use the distributor's invoice as the controlling benefit policy.
Answer key & explanations
1. Answer: B
A: Tempting because supply is necessary, but inventory is already available. B: Correct because authorization is the unresolved benefit function. C: Tempting because purchasing can affect availability, but changing purchase terms does not answer this requirement. D: Tempting because invoice reconciliation is a genuine access operation, but the barrier is not an acquisition-price dispute.
2. Answer: C
A: Tempting because a PBM may adjudicate pharmacy claims, but administration does not establish financing. B: Tempting because the pharmacy receives settlement, but participation in payment does not make it the benefit sponsor. C: Correct because self-funding identifies the employer's financing role. D: Tempting because the administrator organizes participating services, but network administration does not establish claims funding.
3. Answer: A
A: Correct because the stated restriction concerns the designated dispensing location. B: Tempting because chargeback settlement can affect purchasing operations, but no settlement problem is stated. C: Tempting because the health system's purchase access is mentioned, but customer price eligibility is separate from network eligibility. D: Tempting because allocation can limit supply, but the scenario identifies a benefit network restriction.
4. Answer: D
A: Tempting because both involve payment settlement, but the described basis is purchasing rather than a benefit claim. B: Tempting because the transaction concerns a medicine used by patients, but no patient obligation is described. C: Tempting because rebates can adjust net economics, but the explicit basis is an eligible customer's contract purchase-price difference. D: Correct because that difference identifies the stated chargeback arrangement.
5. Answer: B
A: Tempting because a commercial benchmark is familiar, but substituting an unrelated framework preserves the classification error. B: Correct because program and arrangement identification must precede rule application. C: Tempting because both settings involve federal structures, but that shared feature does not establish identical access rules. D: Tempting because an invoice provides a concrete price, but a distribution record is not the controlling benefit document.
Rapid review / cheat-sheet
- Account map → label responsibilities before drawing organizational connections.
- Coverage inquiry → bring the actual benefit response to the responsible owner.
- Funding question → use the arrangement document rather than card branding.
- Network restriction → verify the authorized dispensing location and referral handoff.
- Purchasing dispute → inspect eligibility, units, agreement, and invoice together.
- Financial adjustment → classify by settlement basis before evaluating net economics.
- Federal account → replace the broad label with the named program and purchaser.
- Access completion → confirm the remaining patient-facing handoff.
Key points
- A stakeholder map is a decision tool, not merely a directory.
- Authority, funding, physical custody, and settlement belong on separate layers.
- The best next action resolves the documented barrier with the authorized owner.
See also: FDA Approval and Launch Milestones; Drug Coverage and Reimbursement Routes; Gross-to-Net Revenue and Access. Use these neighboring topics to add timing, pathway, and economic detail to the foundational map.
Keep going with the full US Market Access and Drug Pricing Policy Certificate Program
You just studied the way members do, in the same lesson interface. Full access unlocks every lesson, the question bank and flashcards for a full year.
One payment per program